Sumary of Why Theravance Biopharma Stock Dived 16% Today:
- So what This morning, Theravance divulged the top-line results from its phase 3 study of Ampreloxetine, a drug aimed at treating symptomatic neurogenic orthostatic hypotension (nOH, essentially a disorder in which the body does not effectively regulate blood pressure).
- This was particularly disappointing given that a 2018 phase 2 study showed positive top-line results for Ampreloxetine.
- The news comes less than a month after the biotech company’s drug for inflammatory bowel disease, izencitinib, flopped in a phase 2 trial.
- Which, in turn, was two months after its COVID-19 pipeline drug nezulcitinib fell short in phase 2 testing.